Limited effective therapeutic options are available for patients with recurrent highgrade serous carcinoma (HGSC), the most common histological subtype accounting for the majority of ovarian cancer deaths. We have shown efficacy in poly-ADP ribose polymerase (PARP) inhibitor-resistant HGSC for the RNA Polymerase I (Pol I) transcription inhibitor CX-5461 through its ability to activate a nucleolar-associated DNA damage response (DDR). Here, we screen the protein-coding genome to identify potential targets whose inhibition enhances the efficacy of CX-5461. We identify a network of cooperating inhibitory interactions, including components of homologous recombination (HR) DNA repair and DNA topoisomerase 1 (TOP1). We highlight that CX-5461 combined with topotecan, a TOP1 inhibitor used as salvage therapy in HGSC, induces robust cell cycle arrest and cell death in a panel of HRproficient HGSC cell lines. The combination potentiates a nucleolar-associated DDR via recruitment of phosphorylated replication protein A (RPA) and ataxia telangiectasia and Rad3 related protein (ATR). CX-5461 plus low-dose topotecan cooperate to potently inhibit xenograft tumour growth, indicating the potential for this strategy to improve salvage therapeutic regimens to treat HGSC.
Introduction
High-grade serous carcinoma (HGSC) is the most prevalent histological subtype of epithelial ovarian cancer with the worst prognosis. HGSC is characterised by nearly universal TP53 mutations (>96%), and up to 50% of HGSC harbour defects in homologous recombination (HR) DNA repair genes, including breast cancer related antigen (BRCA)1 and BRCA2, which are necessary for maintaining genomic integrity 1 . Defects in DNA repair confer exquisite sensitivity of HGSC to standard DNAdamaging chemotherapies (carboplatin/cisplatin and paclitaxel) as well as the recently FDA-approved poly-ADP ribose polymerase (PARP) inhibitors (olaparib, rucaparib, niraparib, talazoparib), which are synthetic lethal by generating catastrophic DNA damage and cell death in cells lacking HR 2 . However, resistance to these therapies frequently develops via multiple mechanisms, including restoration of HR leading to disease relapse 3 , highlighting the need to identify new therapeutic targets to overcome resistance. HR-proficient HGSCs including the 20% harbouring CCNE1 amplifications are associated with intrinsic platinum-based chemotherapy resistance and poor clinical outcome 4 . Despite few available salvage therapies, the DNA topoisomerase 1 (TOP1) inhibitor topotecan has shown promise, particularly when combined with the angiogenesis inhibitor Sorafenib in platinum-resistant ovarian cancer 5 .
Increased activation of key oncogenic signalling pathways (PI3K/AKT, RAS/MAPK and MYC) upstream of ribosome biogenesis constitutes an additional hallmark of HGSC 6 , and we hypothesise that inhibiting ribosome biogenesis with the ribosomal RNA gene (rDNA) transcription inhibitor CX-5461 can provide an effective cancer therapeutic option 7 . Indeed, we have shown encouraging responses in a Phase I clinical trial in haematological malignancies 8 , and Canadian trials in breast cancer are ongoing 9 . We have demonstrated in cells with intact p53, CX-5461 induces an impaired ribosome biogenesis checkpoint leading to apoptosis, cell cycle arrest or senescence; however, in cells with inactivated p53 such as HGSC, CX-5461 induces the DNA damage response (DDR) pathway 10 , which is emerging as an attractive clinical target due to the high levels of genomic instability characteristic of HGSC 11 .
We have demonstrated CX-5461 activates the DDR at the nucleoli, the sites of RNA Polymerase I (Pol I) transcription, and exhibits therapeutic efficacy in both PARP inhibitor-sensitive and -resistant HGSC 12 . To uncover additional combination therapies exploiting the non-canonical nucleolar-associated DDR and identify potential targets whose inhibition can enhance the efficacy of CX-5461, we performed a whole protein-coding genome RNAi screen in p53-mutant OVCAR4 cells, which closely resemble the genomic profile of HGSC 13 . We confirmed HR deficiency sensitises HGSC to CX-5461. We also identified that knockdown of TOP1 or treatment with the TOP1 inhibitor topotecan synergises with CX-5461 in multiple HR-proficient HGSC cell lines. Topotecan treatment in the clinic is limited by significant toxicity including myelosuppression 14 ; however, when used in low doses with CX-5461, the combination induces cell death and cell cycle arrest by potentiating the nucleolar DDR without inducing DNA resection. We identify a new therapeutic approach to target HGSC while minimizing the toxicities normally associated with standard of care DNA-damaging therapies.
Materials and Methods

Cell culture
Human HGSC cell lines (OVCAR3, OVCAR4 and CAOV3) were obtained from the National Cancer Institute. All cell lines were short tandem repeat (STR) characterised against American Tissue Type Collection (ATCC) or ExPASy databases to ensure authenticity of origin. Mycoplasma tests were performed routinely by PCR. All cells were cultured in RPMI-1640 media (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma-Aldrich) and 2mM GlutaMax™ (Gibco) at 37°C and 5% CO2.
Reagents and antibodies
CX-5461 was provided by SYNkinase and prepared in 50 mM NaH2PO4. Topotecan (Hycamtin Ò , Novartis) was obtained from the Peter Mac pharmacy and was dissolved in 0.9% saline. DBL ™ doxorubicin hydrochloride injection was purchased from Hospira and diluted in phosphate buffered saline (PBS). The pan-caspase inhibitor Q-VD-OPh (Cat #1901) was purchased from APExBIO and dissolved in dimethyl sulfoxide (DMSO). A list of antibodies used in this study is provided in Supplementary Table S1 .
Genome-wide protein-coding RNAi primary screen and analysis
On a screening day, 160 µL DharmaFECT 4 (Horizon Discovery) was mixed with 50 mL Opti-MEM ® (Gibco) (sufficient for 16 assay plates), and 44 µL lipid:Opti-MEM mixture was then aliquotted to each well of a 384-well black-walled plate (Corning, Cat. #: 3712) containing 6 µL 1 µM SMARTpool siRNA (Horizon Discovery) using a
BioTek EL406™ washer dispenser (final SMARTpool concentration 40 nM). The transfection mixture was mixed and complexed for 20 minutes, and 12.5 µL mixture was then aliquotted into three plates (4 replicate plates in total) using a Caliper Sciclone ALH3000 liquid handler. During this period, OVCAR4 cells were trypsinised and resuspended at 5.6 ´ 10 4 cells/mL. Twenty-five µL OVCAR4 cells (1400 cells) were then dispensed into 384-well plates with the final concentration of the SMARTpool siRNA at 40 nM, and plates were incubated at 37°C and 5% CO2. At 24 h post-transfection, the medium was replaced with cell culture medium containing either 80 nM CX-5461 or 400 nM NaH2PO4. Cells were incubated for another 48 h and fixed with 2% PFA in PBS for 10 min, followed by permeabilisation with 0.3% TritonX-100 in PBS for 10 min. Cells were washed with PBS, stained with 100 ng/mL DAPI for 20 min. Cells were washed twice with PBS and 25 fields were imaged using the ArrayScan VTI high-content system (Thermo Fisher Scientific) with a 20x/0.4 NA objective and an ORCA-ER camera and a 5-ms exposure time. The Cellomics Morphology V4 Bioapplication was used to analyse cell number as determined by DAPI staining.
To identify synergistic gene candidates, we used a combination of the difference in relative cell number between vehicle-and CX-5461-treated target siRNA plates normalised to ON-TARGETplus (Horizon Discovery) non-targeting control (siControl) ³ 0.25, and a value for Bliss independence £ 0.9, which was calculated as follows 15 .
Bliss Independence = (Relative cell number (siRNA + CX-5461)) / (Relative cell number (siRNA + vehicle) ´ Relative cell number (siControl + CX-5461))
Secondary deconvolution screen
Based on the above criteria, we selected 372 genes for a secondary deconvolution screen using the 4 individual siRNA duplexes that comprised the SMARTpool arrayed separately (1 duplex/well). For the secondary screen, the 1 µM SMARTpool siRNAs were replaced by 0.45 µM individual siRNA duplexes for a final concentration of 25 nM/duplex. We modified our selection criteria to define highconfidence hits as those with a difference in relative cell number between vehicleand CX-5461-treated target siRNA plates normalised to siControl ³ 0.15 and Bliss Independence £ 0.8. We classified genes with ³ 2 high-confidence hits as those displaying synergy.
qPCR
The RNeasy ® Mini Kit (Qiagen) was used to extract total RNA as per the manufacturer's instructions. One hundred ng of total RNA was used as a template for cDNA synthesis using SuperScript ™ III reverse transcriptase (Invitrogen ™ #18080093), hexameric random primers and dNTPs. Quantitative real-time PCR (qPCR) reactions were performed using Fast SYBR ® Green reagents in a
StepOnePlus ™ Real-Time PCR system (Applied Biosystems ™ ) with a +0.7°C melt increment. RNase-free water was used as a negative control. Changes in target gene expression were normalised to NONO housekeeping gene and fold change was determined by using 2^(-DDCt). Primer sequences are listed in Supplementary   Table S2 .
Immunoblotting
Cells were washed twice with PBS and whole cell lysates were prepared in Western solubilisation buffer (20 mM HEPES pH 7.9, 2% SDS, 0.5 mM EDTA). Protein was transferred to polyvinylidene fluoride (PVDF) membranes, which were blocked in 5% skim-milk TBS 0.1% Tween® 20 (TBST) for 45 min at RT. Membranes were incubated with primary antibodies overnight at 4°C, washed three times in TBST for 10 min, incubated with HRP-conjugated secondary antibodies for 1 h at room temperature and then washed. Membranes were visualised using Western Lightning ™ Plus enhanced chemiluminescence (Perkin Elmer) by exposure to film (Fujifilm SuperRX) or imaged by a ChemiDoc ™ Touch Imaging System (Bio-Rad Technology). Digital scans of film were acquired using an Epson Perfection V700 Photo at ³ 300dpi.
Immunofluorescence
Five thousand cells were seeded into 8-well Nunc™ Lab-Tek™ II Chamber Slides™ (Cat. #: 154534) per well. Cells were cultured for 72 h, followed by drug treatments at the indicated timepoints and doses together with 10 µM 5-ethynyl-2'-deoxyuridine (EdU) (Sigma-Aldrich, Cat. #900584). Cells were fixed in 4% paraformaldehyde and permeabilised with 0.5% Triton X-100 in PBS. EdU was fluorescently labelled with 0.5 µM Click-iT ™ EdU Alexa Fluor ™ 647 Azide (Invitrogen ™ #A10277) in labelling buffer (100 mM Tris, pH 8.5, 100 mM ascorbic acid, 1 mM CuSO4) for 30 min at room temperature and subsequently stained with the indicated antibodies. Cell nuclei were stained with 500 ng/mL 4',6-diamidino-2-phenylindole (DAPI) diluted in PBS.
Slides were mounted with Vectashield ® Antifade Mounting Media (Vector Laboratories, Cat. #: H-1000). Images were captured by a Zeiss LSM 780 confocal microscope using a 20x/0.8 NA Plan-apochromat objective and were analysed with FIJI 16 and CellProfiler 17 . Quantitation of cell cycle populations was performed using FlowJo software.
Cell cycle analysis
Clonogenic assay
Cells (1 ´ 10 5 /well) were seeded into 6-well plates (BD Falcon). Cells were cultured for 24 h, then drugged as indicated. At 48 h after drug treatment, the drugs were removed by washing twice with PBS. Cells were then cultured in normal medium for another 5 d when the vehicle-treated cells reached confluency. Cells were then fixed with 100% methanol for 10 min, stained with 0.1% crystal violet solution for 20 min, thoroughly washed with PBS and the stained plates were dried, imaged on an IncuCyte ® ZOOM (Essen Bioscience) using a 10x/0.3 NA objective and analysed for cell confluence.
DNA comet assay
DNA comet assays were performed using the CometAssay ® Reagent Kit (Trevigen, Cat. #: 4250-050-K) according to the manufacturer's protocol. Briefly, cells treated with indicated drugs were trypsinised and washed once with ice-cold PBS, and then resuspended in ice-cold PBS at 1 ´ 10 5 cells/mL. Cells were mixed with molten lowmelt agarose at 37°C at a ratio of 1:10 and 50 µL of the mixture was immediately pipetted onto a CometSlide™. The slides were incubated in the dark at 4°C for 30 min to solidify the agarose and immersed in 4°C Lysis Solution overnight. Slides were then immersed in freshly prepared Alkaline Unwinding Solution for 1 h at 4°C in the dark, and electrophoresed in 4°C Alkaline Electrophoresis Solution at 300 mA for 40 min. The slides were washed with ddH2O twice, followed by 70% ethanol for 5 min. Slides were dried at 37°C for 15 min, and then stained with 2.5 µg/mL PI in PBS for 30 min at room temperature. Slides were rinsed twice in ddH2O and completely dried at 37°C. Images were captured using a VS120 Virtual Slide Microscope (Olympus) using a 10x objective and analysed with the OpenComet 18 plugin for ImageJ.
Xenograft transplantation
All animal studies were conducted according to the protocols approved by the Animal Experimentation Ethics Committee at the Peter MacCallum Cancer Centre.
Non-obese diabetic severe-combined immunodeficiency gamma (NSG) mice (6) (7) (8) week-old female) were purchased from the Garvan Institute (Australian BioResources) and housed in animal cages under standard laboratory conditions. 
Results
A functional genomics screen identifies a network of genes that when depleted cooperates with CX-5461 to inhibit HGSC cell proliferation
The Pol I transcription inhibitor CX-5461 has efficacy in a PARP inhibitor-resistant patient-derived xenograft (PDX) model of HGSC 12 . To further identify genes that, when depleted could synergise with CX-5461 to inhibit cell proliferation, we used human OVCAR4 HR-proficient HGSC cells in a protein-coding genome-wide RNAi screen (Fig. 1A) . Based on the reduction in cell number relative to siControl and Bliss Independence to assess combinatorial effects, we identified 372 genes whose knockdown demonstrated synergy with CX-5461 (Table S3 ). Gene ontology analysis identified enrichment in several functional processes, with DNA damage:double-strand break (DSB) repair being the most significant ( Fig. 1B , Table S4 ).
Deconvolution screening using individual siRNA duplexes and more stringent metrics validated 20 genes using a concordance criterion of 2 out of 4 (Table S5 ). STRING network analysis of these genes demonstrated significance in homologous recombination (HR) (Fig. 1C) , consistent with a previous study in breast cancer 20 and our findings that CX-5461 is synthetic lethal with HR deficiency and a HR deficiency gene expression signature predicts HGSC sensitivity to CX-5461 12 .
Notably, treatment of OVCAR4 cells depleted of BRCA2 (4/4 siRNA duplexes validated) with CX-5461 led to significant growth inhibition ( Fig. 1D) , which was associated with micronuclei formation, suggesting enhanced genomic instability ( Fig.   S1A ).
Of the validated candidates, we also identified DNA topoisomerase I (TOP1) (2/4 siRNA duplexes validated), whose physiological function is to relieve DNA supercoiling that occurs during transcription and replication by generating singlestrand breaks (SSBs) 21 . We confirmed TOP1 localization in the nucleus (Fig. S1B ), and its depletion upon siRNA transfection led to a significant decrease in cell number with simultaneous CX-5461 treatment (Fig. 1D ). TOP1 also colocalised with the upstream binding factor (UBF) to the nucleolar periphery ( Fig. S1B) where rDNA is repaired, agreeing with our previous finding that CX-5461 induces nucleolar-specific defects in rDNA chromatin 10, 12 .
CX-5461 and topotecan synergise in inhibiting HGSC cell growth
Given that we observed combinatorial effects between CX-5461 and TOP1 depletion, and the TOP1 inhibitor topotecan is used in salvage therapy for recurrent HGSC, we hypothesised that CX-5461 would be able to extend topotecan's utility.
We investigated how topotecan cooperates with CX-5461 in a panel of three HRproficient HGSC cell lines: OVCAR4, OVCAR3 and CAOV3. We observed drug synergy in all cell lines as quantified by Bliss Independence based on a reduction in cell number ( Fig. 2A) . Clonogenic assays of OVCAR4 cells demonstrated marked suppression of colony formation with the combination of CX-5461 and topotecan compared with either drug alone (Fig. S2A ). Microscopic examination of these cells revealed an enlarged, flattened morphology consistent with a senescence-like phenotype. Indeed, real-time quantitative PCR (qPCR) demonstrated induction of the senescence-associated secretory phenotype (SASP) genes IL1a, IL6 and CXCL8 (Fig. S2B ). We also observed p53-independent transcriptional induction of CDNK1A, which encodes for the cyclin-dependent kinase inhibitor p21. Furthermore, cell cycle analyses of OVCAR4, OVCAR3 and CAOV3 cells demonstrated significant arrest in the G2/M population (Fig. 2B,C) . OVCAR4 and CAOV3 but not OVCAR3 cells also showed a significant increase in the Sub G1 dead cell population (Fig. 2D) , which was partially rescued by the caspase inhibitor Q-VD-OPh, suggesting that the cell death induced by the combination, at least in part, is mediated through apoptosis.
Together, these data demonstrate that the combination of CX-5461 and topotecan induces a senescence-like cell cycle arrest and cell death.
The combination of CX-5461 and topotecan does not induce DNA double-strand breaks or further enhance replication stress
We previously showed the p53-independent response to CX-5461 is mediated by ATM and ATR, both of which are critical regulators of the DDR pathway 10 and are activated by various forms of DNA damage 22 ; hence, we hypothesised that the DDR would be a key mediator of the cellular response to CX-5461 plus topotecan. To test this hypothesis, we first assessed global DDR activation using Western blotting of phosphorylated checkpoint kinases (CHK)1 and CHK2 (downstream effectors of ATR and ATM, respectively), phospho-RPA (Ser33) (a marker of replication stress) and gH2AX (Ser139) (a marker of DNA damage) upon vehicle, CX-5461, topotecan or combination treatment for 3 or 24 h (Fig. 3A) . We observed induction of phospho-CHK2 within 3 h and phospho-CHK1 by 24 h CX-5461 or topotecan treatment, which was markedly increased with the combination. At 24 h, in addition to phospho-CHK1 and phospho-CHK2, we also found a robust increase in phospho-RPA, indicating increased ssDNA. However, this did not translate to increased DSB formation, as we only observed gH2AX upon treatment with doxorubicin, a DNA topoisomerase 2 (TOP2) inhibitor known to cause DSBs, suggesting the combination of CX-5461 and topotecan may act via a distinct mechanism. Consistent with this hypothesis, alkaline comet assays of OVCAR4 cells revealed CX-5461 and topotecan as single agents or in combination did not induce comet tails, unlike doxorubicin (Fig. 3B) . Thus, CX-5461, topotecan or the combination can induce the DDR without DNA resection.
We have shown that the CX-5461-mediated DDR is associated with degradation of stalled replication forks and replication-dependent DNA damage in HGSC cells 12 . To determine if the combination of CX-5461 and topotecan induced further replication stress, we stained for RAD51 and γH2AX foci formation in OVCAR4 cells treated with 5-ethynyl-2'-deoxyuridine (EdU) to mark S-phase cells (Fig. 3C ). Consistent with our previous finding, CX-5461 treatment increased RAD51 (Fig. 3D ) and γH2AX ( Fig. 3E) foci formation in EdU-positive cells compared to the EdU-negative cells, as expected for the induction of replication stress. Topotecan treatment also increased RAD51 and γH2AX foci formation; however, CX-5461 plus topotecan did not lead to a further enhancement.
Combined treatment of CX-5461 and topotecan potentiates a nucleolar-associated DDR
As we have demonstrated CX-5461 alone induces the formation of ssDNA and recruitment of phosphorylated RPA to rDNA 12 , we examined nucleolar recruitment of phosphorylated RPA (Fig. 4A ) and found robust nucleolar localization of phospho-RPA with the combination treatment, particularly in replicating cells. We also examined the localization of phosphorylated ATR, which is recruited to RPA-coated ssDNA (Fig. 4B) . Treatment with CX-5461 alone or in combination with topotecan enhanced nucleolar phospho-ATR staining as compared to vehicle. Furthermore, while nucleolar phospho-RPA was robustly induced upon doxorubicin treatment, phospho-ATR was not. Together, these data demonstrate that CX-5461 plus topotecan induces the RPA-ATR DDR axis within the nucleoli and a robust G2/M cell cycle arrest and cell death via a mechanism distinct from the standard DNAdamaging cytotoxic drug doxorubicin. Thus, we posit that a nucleolar-specific activation of the DDR will maintain treatment efficacy with reduced genotoxicity compared with standard cytotoxic drugs used to treat HGSC.
CX-5461 plus topotecan delays HGSC xenograft progression
Topotecan is a primary salvage therapy for platinum-resistant HGSC but haematological suppression has restricted its long-term use in the clinic 23 .
Therefore, we hypothesised that the nucleolar-specific DDR induced by combining topotecan with CX-5461 would enable increased efficacy with less toxicity than single agent topotecan at the maximum tolerated dose (MTD). We established tumours from HR-proficient OVCAR3 cells harbouring amplified CCNE1, which confers primary treatment resistance and poor outcome of HGSC 4 , and assessed tumour growth and survival in response to treatment with CX-5461 (30 mg/kg), topotecan (5 mg/kg) or CX-5461 plus topotecan (Fig. 5A ). We chose a topotecan dosage of 5 mg/kg to mitigate the potential hematologic toxicity observed at higher doses (12.5 mg/kg) 24 . Mice were dosed twice weekly for 4 weeks and then monitored until the animals reached an ethical endpoint. CX-5461 or topotecan treatment alone delayed tumour growth and prolonged survival as compared to vehicle treatment. Strikingly, the combined treatment of CX-5461 and topotecan blocked tumour progression during the entirety of drug treatment, extending survival.
The combination was well tolerated with a mean weight loss < 10%. To test whether further reduction of the topotecan dose could retain therapeutic efficacy of the combination, we performed a second experiment using half the topotecan dose (2.5 mg/kg) of the first experiment (5 mg/kg) (Fig. 5B ). In this setting, the combined treatment of CX-5461 and topotecan still significantly reduced tumour growth and extended overall survival compared to topotecan alone.
Discussion
We previously demonstrated that CX-5461 induces a nucleolar-associated DDR and is synthetic lethal with HR deficiency in vitro and in vivo in HGSC via a mechanism that is distinct from PARP inhibitors 12 . Here, our genome-wide siRNA screen identified a number of genes involved in DNA repair (Table S4) including TOP1, which when depleted cooperate with CX-5461 to impair HGSC growth. We showed that CX-5461 the TOP1 inhibitor topotecan used in HGSC salvage therapy induces cell cycle arrest and cell death in multiple HGSC cell lines by potentiating a 15 nucleolar-associated DDR, independent of DNA resection. The combination was also effective using low-dose topotecan in HGSC xenografts, thus providing a strategy to facilitate dose reduction to minimise the potential for toxicity while retaining efficacy to treat HGSC. In addition to confirming the importance of HR deficiency conferring sensitivity to CX-5461 in HGSC as we and others have shown 12, 20 , we found TOP1 inhibition can cooperate with CX-5461 in the HR-proficient context, thereby potentially expanding the application of CX-5461 to a larger HGSC cohort, including patients previously harbouring HR-deficient tumours that have acquired chemotherapeutic resistance due to restored HR.
We demonstrated CX-5461 plus low-dose topotecan induces robust phosphorylation of RPA and ATR within the nucleolus. Together with our previous finding that CX-5461 enhances rDNA accessibility to MNase 10 , we hypothesise that the combination further alters rDNA topology, which may occur via R loops 12 or G4-quadruplex DNA 20 , to potentiate the DDR. Importantly, this nucleolar-associated DDR is less genotoxic than other DNA-damaging therapies such as doxorubicin, which does not activate nucleolar phospho-ATR but induces deleterious DSBs. Thus, CX-5461 plus topotecan represents a promising targeted approach for exploiting the nucleolarassociated DDR to improve salvage therapy.
Cellular senescence has been reported to be a central response to cytotoxic chemotherapy in HGSC 25 . Indeed, we observed that a key cellular response of HGSC to CX-5461 plus topotecan is a G2/M cell cycle arrest and a senescence-like phenotype, which occurs through an enhanced nucleolar DDR without DNA resection. We posit that this can be further exploited in combination therapies with Quantification of the percentage of G1, Early S, Late S and G2 phase cells in (B) is presented as mean ± SEM and statistical significance was determined by Kruskal-
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Wallis one-way ANOVA (*, P < 0.05; **, P < 0.01; ****, P < 0.001; ****, P < 0.0001).
(D) Quantification of the percentage of Sub G1 cells treated with control (DMSO) or 10 µM Q-VD-OPh is presented as mean ± SEM and statistical significance was determined by one-way ANOVA (*, P < 0.05; **, P < 0.01; ****, P < 0.001), (##, P < 0.01; ###, P < 0.001 for Q-VD-OPh as compared with DMSO control). 
